Abbott Laboratories [ABT] stock is trading at $137.4, down -0.49%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ABT shares have gain 3.87% over the last week, with a monthly amount glided 4.65%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Abbott Laboratories [NYSE: ABT] stock has seen the most recent analyst activity on June 16, 2025, when Leerink Partners initiated its Market Perform rating and assigned the stock a price target of $143. Previously, Oppenheimer started tracking the stock with Outperform rating on October 08, 2024, and set its price target to $130. On September 19, 2024, Piper Sandler initiated with a Overweight rating and assigned a price target of $131 on the stock. Edward Jones downgraded its rating to a Hold. Goldman initiated its recommendation with a Buy and recommended $121 as its price target on May 30, 2024. Wolfe Research upgraded its rating to Peer Perform for this stock on July 21, 2023. In a note dated May 30, 2023, Morgan Stanley downgraded an Equal-Weight rating on this stock but restated the target price of $112.
Abbott Laboratories [ABT] stock has fluctuated between $99.71 and $141.23 over the past year. Currently, Wall Street analysts expect the stock to reach $137.5 within the next 12 months. Abbott Laboratories [NYSE: ABT] shares were valued at $137.4 at the most recent close of the market. An investor can expect a potential return of 0.07% based on the average ABT price forecast.
Analyzing the ABT fundamentals
Abbott Laboratories [NYSE:ABT] reported sales of 42.34B for the trailing twelve months, which represents a growth of 3.95%. Gross Profit Margin for this corporation currently stands at 0.56% with Operating Profit Margin at 0.17%, Pretax Profit Margin comes in at 0.17%, and Net Profit Margin reading is 0.32%. To continue investigating profitability, this company’s Return on Assets is posted at 0.17, Equity is 0.31 and Total Capital is 0.1. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.27.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 136.41 points at the first support level, and at 135.43 for the second support level. However, for the 1st resistance point, the stock is sitting at 138.61, and for the 2nd resistance point, it is at 139.83.
Ratios To Look Out For
For context, Abbott Laboratories’s Current Ratio is 1.78. As well, the Quick Ratio is 1.27, while the Cash Ratio is 0.5. Considering the valuation of this stock, the price to sales ratio is 5.65, the price to book ratio is 4.90 and price to earnings (TTM) ratio is 17.82.
Transactions by insiders
Recent insider trading involved Blount Sally E., Director, that happened on Apr 30 ’25 when 2600.0 shares were sold. Director, SALLY E BLOUNT completed a deal on Apr 30 ’25 to buy 2600.0 shares. Meanwhile, EVP AND GROUP PRESIDENT Earnhardt Lisa D sold 91167.0 shares on Mar 06 ’25.
